Armata Pharmaceuticals Inc.

ARMP

We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an esse…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$117M

EPS-$7.58

P/E-0.41

P/FCF-4.53

EV/EBITDA-4.06

FCF Yield–

Div. Yield–

Net Debt/FCF-1.9x

Armata Pharmaceuticals Inc. intrinsic value

52-Week Range

$2.78$9.36

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$192M

▼ -818.8% YoY

Op. Margin

–

ROIC

-21.81%

▲ +18.3pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$26M

▲ +33.3% YoY

Op. Cash Flow (TTM)

-$25M

▲ +31.4% YoY

Net Debt

$49M

Cash & Equiv.

$24M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ARMP

CompareIntrinsic value

PALIPalisade Bio Inc.

$1.25+1.63%20

CRDFCardiff Oncology Inc.

$0.87+1.03%36

BCABBioAtla, Inc.

$2.00+0.00%0

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ATYRAtyr Pharma Inc.

$6.18-6.79%10

VIVSVivoSim Labs, Inc.

$0.15+8.71%10

AIMAIM ImmunoTech Inc.

$0.16+0.63%15

Armata Pharmaceuticals (ARMP) in three numbers

Quality score: 30/100; Best check: revenue growth, 404.9%. Weakest: return on capital, -21.8%.; Quality
Dividend: None; Last paid in 2016, nothing since.; Dividends
P/E: -0.41; Negative: a loss over the last twelve months. Price to free cash flow -4.53.; Financials

Questions about Armata Pharmaceuticals

Is Armata Pharmaceuticals a high-quality business?

Armata Pharmaceuticals scores 30 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 404.9%, and its weakest is return on capital at -21.8%. The Quality tab shows every check against its target.

Does Armata Pharmaceuticals (ARMP) pay a dividend?

No. Armata Pharmaceuticals (ARMP) does not currently pay a dividend. The last payment in our data was in 2016, and nothing has been paid since. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 6 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ARMP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARMP

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.